Calcort supply to end in Canada once remaining stock is gone, Duchenne groups say
Three patient organizations say Cheplapharm will stop supplying Calcort (deflazacort) once stock runs out. They are seeking details on what remains and exploring other sources.
In this article & details
Cheplapharm will stop supplying Calcort (deflazacort) to Canada once existing inventory is exhausted, three Duchenne muscular dystrophy organizations said on Nov. 11. Muscular Dystrophy Canada, Defeat Duchenne Canada and La Force DMD said they received written confirmation from the manufacturer, which cited problems with manufacturing and supply. Canada has historically received UK-labelled stock. Joint update
Patient groups seek details on remaining stock
The groups say they are working to establish which strengths remain available and how the stock will be distributed. They also want to identify other sources of deflazacort and determine what regulatory steps would be needed to make them accessible. Their Nov. 11 update gave no date for stock to run out. They directed families with questions about treatment changes to their treating clinicians, who can weigh clinical suitability, availability and cost. Access and continuity plans
Health Canada recorded 417 special-access requests in 2025
Health Canada lists Calcort among drugs accessed through its Special Access Program, which can make drugs unavailable for sale in Canada accessible on request. Its 2025 figures show 417 requests that led to access for Calcort tablets. The count measures requests rather than individual patients, and the listing itself does not establish current supply. Special Access Program data
Deflazacort is a corticosteroid used in Duchenne care. The three-year FOR-DMD randomized trial found better results on a combined measure of motor function, lung function and treatment satisfaction with either daily deflazacort or daily prednisone than with intermittent prednisone. The trial did not find a statistically significant difference between the two daily regimens on that measure. FOR-DMD trial
References
- Update on Calcort (deflazacort) availability in Canada — Muscular Dystrophy Canada, Defeat Duchenne Canada and La Force DMD, Joint update, Nov. 11, 2026
- Defeat Duchenne Canada: Joint update on Calcort (deflazacort) availability in Canada — Defeat Duchenne Canada, Joint update, Nov. 11, 2026
- Special access drugs: Most often requested — Health Canada, Jan. 1 to Dec. 31, 2025 data
- Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial — Guglieri and colleagues, JAMA, FOR-DMD trial, April 2022
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.